vs
AMCON DISTRIBUTING CO（DIT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是AMCON DISTRIBUTING CO的1.1倍（$772.1M vs $730.1M），Revvity净利率更高（12.7% vs 0.1%，领先12.6%），Revvity同比增速更快（5.9% vs 2.6%），Revvity自由现金流更多（$161.8M vs $-12.4M），过去两年AMCON DISTRIBUTING CO的营收复合增速更高（10.1% vs 9.0%）
AMCON Distributing Co是一家总部位于美国的消费品分销企业，主营食品、饮料、美妆个护、烟草及日用百货的分销业务，主要服务美国本土的独立便利店、食品零售商、药店及其他小型零售网点。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DIT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$730.1M
营收增速更快
RVTY
高出3.2%
2.6%
净利率更高
RVTY
高出12.6%
0.1%
自由现金流更多
RVTY
多$174.2M
$-12.4M
两年增速更快
DIT
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $730.1M | $772.1M |
| 净利润 | $793.0K | $98.4M |
| 毛利率 | 6.6% | — |
| 营业利润率 | 0.5% | 14.5% |
| 净利率 | 0.1% | 12.7% |
| 营收同比 | 2.6% | 5.9% |
| 净利润同比 | 127.6% | 3.9% |
| 每股收益（稀释后） | $1.28 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DITRVTY
| Q4 25 | $730.1M | $772.1M | ||
| Q3 25 | $746.3M | $698.9M | ||
| Q2 25 | $739.6M | $720.3M | ||
| Q1 25 | $619.5M | $664.8M | ||
| Q4 24 | $711.3M | $729.4M | ||
| Q3 24 | $746.3M | $684.0M | ||
| Q2 24 | $717.9M | $691.7M | ||
| Q1 24 | $601.9M | $649.9M |
净利润DITRVTY
| Q4 25 | $793.0K | $98.4M | ||
| Q3 25 | $491.7K | $46.7M | ||
| Q2 25 | $1.3M | $53.9M | ||
| Q1 25 | $-1.6M | $42.2M | ||
| Q4 24 | $348.4K | $94.6M | ||
| Q3 24 | $1.2M | $94.4M | ||
| Q2 24 | $1.5M | $55.4M | ||
| Q1 24 | $539.5K | $26.0M |
毛利率DITRVTY
| Q4 25 | 6.6% | — | ||
| Q3 25 | 6.5% | 53.6% | ||
| Q2 25 | 6.7% | 54.5% | ||
| Q1 25 | 6.9% | 56.5% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 6.5% | 56.3% | ||
| Q2 24 | 6.7% | 55.7% | ||
| Q1 24 | 7.0% | 54.6% |
营业利润率DITRVTY
| Q4 25 | 0.5% | 14.5% | ||
| Q3 25 | 0.5% | 11.7% | ||
| Q2 25 | 0.7% | 12.6% | ||
| Q1 25 | 0.1% | 10.9% | ||
| Q4 24 | 0.5% | 16.3% | ||
| Q3 24 | 0.7% | 14.3% | ||
| Q2 24 | 0.8% | 12.4% | ||
| Q1 24 | 0.6% | 6.8% |
净利率DITRVTY
| Q4 25 | 0.1% | 12.7% | ||
| Q3 25 | 0.1% | 6.7% | ||
| Q2 25 | 0.2% | 7.5% | ||
| Q1 25 | -0.3% | 6.4% | ||
| Q4 24 | 0.0% | 13.0% | ||
| Q3 24 | 0.2% | 13.8% | ||
| Q2 24 | 0.2% | 8.0% | ||
| Q1 24 | 0.1% | 4.0% |
每股收益（稀释后）DITRVTY
| Q4 25 | $1.28 | $0.86 | ||
| Q3 25 | $0.80 | $0.40 | ||
| Q2 25 | $2.13 | $0.46 | ||
| Q1 25 | $-2.58 | $0.35 | ||
| Q4 24 | $0.57 | $0.77 | ||
| Q3 24 | $2.02 | $0.77 | ||
| Q2 24 | $2.46 | $0.45 | ||
| Q1 24 | $0.89 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $114.1M | $7.3B |
| 总资产 | $378.7M | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DITRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务DITRVTY
| Q4 25 | — | — | ||
| Q3 25 | $16.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $21.8M | — | ||
| Q2 24 | $23.3M | — | ||
| Q1 24 | $20.5M | — |
股东权益DITRVTY
| Q4 25 | $114.1M | $7.3B | ||
| Q3 25 | $113.1M | $7.4B | ||
| Q2 25 | $113.2M | $7.6B | ||
| Q1 25 | $111.4M | $7.6B | ||
| Q4 24 | $112.4M | $7.7B | ||
| Q3 24 | $111.7M | $7.9B | ||
| Q2 24 | $110.0M | $7.9B | ||
| Q1 24 | $108.0M | $7.8B |
总资产DITRVTY
| Q4 25 | $378.7M | $12.2B | ||
| Q3 25 | $391.1M | $12.1B | ||
| Q2 25 | $393.9M | $12.4B | ||
| Q1 25 | $392.0M | $12.4B | ||
| Q4 24 | $404.7M | $12.4B | ||
| Q3 24 | $374.1M | $12.8B | ||
| Q2 24 | $400.6M | $13.4B | ||
| Q1 24 | $336.2M | $13.4B |
负债/权益比DITRVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-12.4M | $161.8M |
| 自由现金流率自由现金流/营收 | -1.7% | 21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.6% |
| 现金转化率经营现金流/净利润 | -14.75× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $40.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DITRVTY
| Q4 25 | $-11.7M | $182.0M | ||
| Q3 25 | $31.1M | $138.5M | ||
| Q2 25 | $-7.0M | $134.3M | ||
| Q1 25 | $34.4M | $128.2M | ||
| Q4 24 | $-39.9M | $174.2M | ||
| Q3 24 | $41.0M | $147.9M | ||
| Q2 24 | $-26.9M | $158.6M | ||
| Q1 24 | $48.8M | $147.6M |
自由现金流DITRVTY
| Q4 25 | $-12.4M | $161.8M | ||
| Q3 25 | $30.4M | $120.0M | ||
| Q2 25 | $-8.8M | $115.5M | ||
| Q1 25 | $31.4M | $112.2M | ||
| Q4 24 | $-43.3M | $149.8M | ||
| Q3 24 | $37.4M | $125.6M | ||
| Q2 24 | $-32.6M | $136.6M | ||
| Q1 24 | $41.6M | $129.7M |
自由现金流率DITRVTY
| Q4 25 | -1.7% | 21.0% | ||
| Q3 25 | 4.1% | 17.2% | ||
| Q2 25 | -1.2% | 16.0% | ||
| Q1 25 | 5.1% | 16.9% | ||
| Q4 24 | -6.1% | 20.5% | ||
| Q3 24 | 5.0% | 18.4% | ||
| Q2 24 | -4.5% | 19.7% | ||
| Q1 24 | 6.9% | 20.0% |
资本支出强度DITRVTY
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.5% | 3.3% | ||
| Q2 24 | 0.8% | 3.2% | ||
| Q1 24 | 1.2% | 2.7% |
现金转化率DITRVTY
| Q4 25 | -14.75× | 1.85× | ||
| Q3 25 | 63.32× | 2.97× | ||
| Q2 25 | -5.33× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | -114.43× | 1.84× | ||
| Q3 24 | 33.16× | 1.57× | ||
| Q2 24 | -18.05× | 2.87× | ||
| Q1 24 | 90.37× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DIT
| Cigarettes | $446.5M | 61% |
| Tobacco | $143.7M | 20% |
| Tobacco Food Service And Other | $82.3M | 11% |
| Confectionery | $46.7M | 6% |
| Retail Segment | $10.8M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
